![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Population pharmacokinetic analysis for darunavir and tenofovir
alafenamide in HIV-1-infected patients on the darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (AMBER and EMERALD studies)
|
|
|
Reported By Jules Levin
19th International Workshop on ClinicalPharmacologyof AntiviralTherapy, 22 -24 May2018, Baltimore, Maryland, USA
Ackaert O1, McDougall D2, Perez Ruixo C1, Crauwels
H1
1Janssen Research and Development, Beerse, Belgium, 2Model Answers
Pty Ltd., Brisbane , Australia
![0604181](../images%20/060418/060418-3/0604181.gif)
![0604182](../images%20/060418/060418-3/0604182.gif)
![0604183](../images%20/060418/060418-3/0604183.gif)
![0604184](../images%20/060418/060418-3/0604184.gif)
![0604185](../images%20/060418/060418-3/0604185.gif)
![0604186](../images%20/060418/060418-3/0604186.gif)
![0604187](../images%20/060418/060418-3/0604187.gif)
![0604188](../images%20/060418/060418-3/0604188.gif)
![0604189](../images%20/060418/060418-3/0604189.gif)
![06041810](../images%20/060418/060418-3/06041810.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|